论文部分内容阅读
目的:探讨乌丹降脂胶囊治疗大鼠非酒精性脂肪肝(NASH)的作用及可能的治疗机制。方法:90只大鼠随机分为6组,分别为正常对照组、模型对照组、易复善组和乌丹降脂胶囊104.17 mg/kg、208.34 mg/kg、416.67 mg/kg剂量组。正常对照组以基础饲料喂食,而模型对照组、易复善组和乌丹降脂胶囊104.17 mg/kg、208.34 mg/kg、416.67 mg/kg剂量组则以高脂饲料喂饲,连续喂养16周;喂养2周后,正常对照组、模型对照组以生理盐水10ml/kg灌胃;易复善组以易复善溶液灌胃85.2mg/kg;乌丹降脂胶囊104.17 mg/kg、208.34 mg/kg、416.67 mg/kg剂量组以乌丹降脂胶囊不同浓度溶液灌胃10ml/kg,连续灌胃14周,测量大鼠体重、肝湿重、肝指数,检测血清生化指标及肝组织病理改变。结果:与模型组相比,乌丹降脂胶囊416.67 mg/kg组及易复善组体重、肝湿重及肝指数均明显降低,血液生化ALT、AST、CHOL、TG、LDL-C、CRP各指标水平明显下降,HDL-C水平明显升高;与模型组相比,病理HE染色结果显示,易复善组与乌丹降脂胶囊416.67 mg/kg组肝脏肝小叶结构恢复,肝细胞索及肝窦结构清晰,肝细胞内脂肪空泡显著减少。结论:乌丹降脂胶囊具有治疗非酒精性脂肪肝作用,机制可能与调节脂质代谢有关。
Objective: To investigate the effect of Wu Dan Jiang Zhi Capsule in the treatment of non-alcoholic fatty liver disease (NASH) in rats and its possible therapeutic mechanism. Methods: Ninety rats were randomly divided into six groups, namely normal control group, model control group, Yi Fu Shan group and Wudang Jiangzhi Capsule 104.17 mg / kg, 208.34 mg / kg and 416.67 mg / kg. The normal control group was fed with basal diet, while the model control group, Yi Fu Shan group and Wu Dan Jiang Zhi Capsule 104.17 mg / kg, 208.34 mg / kg and 416.67 mg / kg dose groups were fed with high fat diet and fed continuously for 16 Week. After 2 weeks of feeding, the normal control group and the model control group were given gavage with saline 10ml / kg; the Yifunshan group was given Ganxian solution 85.2mg / kg; the WUDAN Jiangzhi Capsule 104.17 mg / kg and 208.34 mg / kg, 416.67 mg / kg dose group were treated with different concentrations of Wudang Jiangzhi capsule by intragastric administration of 10ml / kg for 14 weeks. The body weight, liver wet weight and liver index were measured. Serum biochemical indexes and liver tissues Pathological changes. Results: Compared with the model group, the body weight, liver wet weight and liver index of 416.67 mg / kg group and Yi-Fu-yan group were significantly decreased, while the contents of ALT, AST, CHOL, TG, LDL-C and CRP Compared with the model group, the pathological HE staining showed that the hepatic lobule structure of the YiFuShan group and the 416.5 mg / kg group of WuDanJiangzhi capsule recovered, and the level of HDL-C was significantly increased And sinusoidal structure is clear, significantly reduced hepatic fat vacuoles. Conclusion: Wu Dan Jiangzhi Capsule has the effect of treating non-alcoholic fatty liver disease, which may be related to the regulation of lipid metabolism.